A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

by palligoelme@gmail.com | Feb 24, 2026 | Clinical Trials

​ Conditions: Meningioma Interventions: Drug: Zanzalintinib Sponsors: Exelixis Not yet recruiting Conditions: Meningioma Interventions: Drug: Zanzalintinib Sponsors: Exelixis Not yet recruiting 

REVIVE Prospective Registry Cohort Study

by palligoelme@gmail.com | Feb 24, 2026 | Clinical Trials

​ Conditions: Oropharyngeal Dysphagia Interventions: Other: Other: No Intervention (subjects were previously treated with Iltamiocel). This is a observational study and all participants will be observed with no intervention. Sponsors: Peter Belafsky, MD; Cook MyoSite...

Ultrasound-Guided Radiofrequency Ablation Versus Steroid Injection for Stump Neuroma

by palligoelme@gmail.com | Feb 24, 2026 | Clinical Trials

​ Conditions: Stump Neuroma; Residual Limb Pain; Lower Extremity Amputation Interventions: Procedure: Radiofrequency ablation alone; Drug: Corticosteroid Injection Sponsors: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital...

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson’s Disease

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Essential Tremor, Movement Disorders; Essential Tremor; Essential Tremor-plus Sponsors: CND Life Sciences; National Institute of Neurological Disorders and Stroke (NINDS) Recruiting Conditions: Essential Tremor, Movement Disorders; Essential Tremor;...

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Hereditary Angioedema (HAE); Hereditary Angioedema – Type 1; Hereditary Angioedema – Type 2; HAE Interventions: Drug: ADX-324 Dose Level 1; Drug: ADX-324 Dose Level 2 Sponsors: ADARx Pharmaceuticals, Inc. Not yet recruiting Conditions:...